The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc., Novo Nordisk A/S, Biodel Inc., and DURECT Corp.
New York headquartered Synergy Pharmaceuticals Inc.’s shares gained 2.19%, closing Wednesday’s trading session at $4.20. The stock recorded a trading volume of 1.38 million shares. Shares of the Company have advanced 9.95% in the last month and 44.83% in the previous three months. The stock is trading 9.82% above its 50-day moving average. Additionally, shares of Synergy Pharmaceuticals, which focuses on the development of drugs to treat gastrointestinal disorders and diseases, have a Relative Strength Index (RSI) of 61.12.
On July 15th, 2016, Synergy Pharmaceuticals announced that it has reached the FDA’s mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). Furthermore, the company has decided to continue patient enrollment for its two ongoing phase 3 clinical trials with plecanatide in IBS-C. The decision to continue enrollment comes after trial monitoring demonstrated a slower enrollment pace combined with an increase in the number of patients not meeting randomization criteria after the screening period prior to starting treatment.
On Wednesday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 2.48 million shares, which was above their three months average volume of 1.38 million shares. The stock fell 1.14%, ending the day at $55.35. The Company’s shares have advanced 2.07% in the last month and 2.90% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.17% and 2.14%, respectively. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 47.40.
On August 2nd, 2016, Bloomberg reported that Novo Nordisk A/S’s Victoza, a diabetes treatment that dominates its class of drugs, was shunned by U.S. pharmacy benefits manager Express Scripts Holding Co. for at least the second year in a row, signaling that the Danish company refused to concede on pricing. Victoza, the market leader among drugs known as GLP-1 analogs that stimulate insulin production, is forecasted to generate sales of $3.09 billion this year, according to analysts’ estimates compiled by Bloomberg.
Danbury, Connecticut headquartered Biodel Inc.’s stock finished the day 5.00% lower at $0.40 and with a total volume of 324,914 shares traded. The Company’s shares have gained 28.71% in the last one month, 7.84% in the previous three months, and 17.35% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 16.33% and 19.60%, respectively. Additionally, shares of Biodel, which focuses on the development and commercialization of treatments for diabetes in the United States, have an RSI of 59.05.
Shares in Cupertino, California headquartered DURECT Corp. ended yesterday’s session 2.17% higher at $1.88. The stock recorded a trading volume of 659,113 shares. The Company’s shares have surged 57.98% in the last one month and 32.39% over the previous three months. The stock is trading 36.33% above its 50-day moving average and 21.48% above its 200-day moving average. Moreover, shares of DURECT, which researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms, have an RSI of 72.78.
On August 1st, 2016, DURECT announced that for the Q2 2016 total revenues were $3.2 million and net loss was for$9.0 million as compared to total revenues of $4.4 million and net loss of $5.5 million for the Q2 2015. As of June 30th, 2016, DURECT had cash and investments of $33.9 million compared to cash and investments of $29.3 millionat December 31st, 2015.
Learn more about these stocks by downloading their comprehensive and free reports at: http://stock-callers.com/registration.